JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

JNJ

227.3

-0.24%↓

ISRG

507.91

-2.78%↓

ABT

106.03

+0.05%↑

MDT

100.97

+0.31%↑

A

133.13

-0.58%↓

Search

Simulations Plus Inc

Cerrado

SectorSanidad

17.68 -5.4

Resumen

Variación precio

24h

Actual

Mínimo

17.23

Máximo

18.69

Métricas clave

By Trading Economics

Ingresos

1.4M

676K

Ventas

961K

18M

P/B

Media del Sector

48.528

90.422

BPA

-0.034

Rentabilidad por dividendo

0.48

Margen de beneficios

3.67

Empleados

212

EBITDA

-3M

2.3M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

-2.91% downside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.48%

2.13%

Próximas Ganancias

2 abr 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

37M

405M

Apertura anterior

23.08

Cierre anterior

17.68

Noticias sobre sentimiento de mercado

By Acuity

100%

0%

334 / 352 Clasificación en Healthcare

Simulations Plus Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

28 ene 2026, 23:51 UTC

Ganancias

Correction to Samsung Fourth-Quarter Net Profit Article

28 ene 2026, 23:49 UTC

Acciones populares

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

28 ene 2026, 23:19 UTC

Ganancias

Samsung's Fourth-Quarter Net Profit Beats Consensus

28 ene 2026, 22:43 UTC

Ganancias

Waste Management Logs Higher 4Q Profit as Revenue Rises

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

29 ene 2026, 00:00 UTC

Adquisiciones, fusiones, absorciones

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

28 ene 2026, 23:49 UTC

Charlas de Mercado

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

28 ene 2026, 23:30 UTC

Charlas de Mercado

Tesla to Use Car Factory for Robot Aims -- Market Talk

28 ene 2026, 23:28 UTC

Ganancias

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

28 ene 2026, 23:26 UTC

Ganancias

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

28 ene 2026, 23:21 UTC

Ganancias

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 ene 2026, 23:18 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 ene 2026, 22:58 UTC

Ganancias

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 ene 2026, 22:48 UTC

Charlas de Mercado

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

28 ene 2026, 22:45 UTC

Ganancias

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

28 ene 2026, 22:44 UTC

Ganancias

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

28 ene 2026, 22:43 UTC

Ganancias

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

28 ene 2026, 22:41 UTC

Ganancias
Acciones populares

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

28 ene 2026, 22:41 UTC

Charlas de Mercado

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

28 ene 2026, 22:41 UTC

Ganancias

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

28 ene 2026, 22:40 UTC

Ganancias

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

28 ene 2026, 22:39 UTC

Ganancias

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

28 ene 2026, 22:38 UTC

Ganancias

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

28 ene 2026, 22:37 UTC

Ganancias

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

28 ene 2026, 22:35 UTC

Ganancias

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 ene 2026, 22:26 UTC

Charlas de Mercado
Ganancias

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

28 ene 2026, 22:20 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

28 ene 2026, 22:20 UTC

Charlas de Mercado

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Comparación entre iguales

Cambio de precio

Simulations Plus Inc previsión

Precio Objetivo

By TipRanks

-2.91% descenso

Estimación a 12 Meses

Media 19 USD  -2.91%

Máximo 19 USD

Mínimo 19 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Simulations Plus Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

2

Comprar

3

Mantener

0

Vender

Sentimiento

By Acuity

334 / 352 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat